Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

BACKGROUND: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC. METHODS: Patien...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Int J Clin Oncol
المؤلفون الرئيسيون: Uemura, Hirotsugu, Uemura, Hiroji, Nagamori, Satsohi, Wakumoto, Yoshiaki, Kimura, Go, Kikukawa, Hiroaki, Yokomizo, Akira, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Akagawa, Takashi, Matsubara, Nobuaki
التنسيق: Artigo
اللغة:Inglês
منشور في: Springer Singapore 2019
الموضوعات:
Original Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469691/
https://ncbi.nlm.nih.gov/pubmed/30875000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-018-01389-4
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة